Amunix, Inc.

Mountain View, CA 94043

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $2.37MM
First Award Date 04/15/07
Most Recent Award Date 08/01/12

Key Personnel

Last Name Name Awards Contact
Schellenberger Volker Schellenberger 7

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 08/01/12 - 07/31/13

DESCRIPTION (provided by applicant): Enfuvirtide (Fuzeon, T-20) is a peptide HIV entry inhibitor currently dosed twice daily by subcutaneous injection. While proven to be efficacious and safe, enfuvirtide is under-utilized due to its frequent dosing, cumbersome administration, and inducement of injection site reactions in most patients. In expre...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/09 - 08/31/11

DESCRIPTION (provided by applicant): Treatment of metastatic tumors is a major health challenge. Recently, antibody-based therapies have been developed that are more specific and have fewer side effects compared with conventional chemotherapy. However, the potency of most antibody therapeutics is limited by their inadequate ability to kill tumor...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/01/09 - 02/28/10

DESCRIPTION (provided by applicant): The market for protein-based biopharmaceuticals is rapidly expanding. However, the clinical utility of many proteins is limited by their short serum half-life, requiring frequent injections. The most common approach to improve serum half-life is PEGylation. The chemical conjugation of Polyethylene glycol (PEG...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-50
Budget: 09/15/08 - 08/31/09

DESCRIPTION (provided by applicant): Treatment of metastatic tumors is a major health challenge. Recently, antibody-based therapies have been developed that are more specific and have fewer side effects compared with conventional chemotherapy. However, the potency of most antibody therapeutics is limited by their inadequate ability to kill tumor...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/01/08 - 08/31/09

DESCRIPTION (provided by applicant): The market for protein-based biopharmaceuticals is rapidly expanding. However, the clinical utility of many proteins is limited by their short serum half-life, requiring frequent injections. The most common approach to improve serum half-life is PEGylation. The chemical conjugation of Polyethylene glycol (PEG...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 09/06/07 - 07/31/08

DESCRIPTION (provided by applicant): Targeted delivery of cytotoxic drugs to tumor tissues is an effective strategy to minimize drug exposure of normal tissues and thus improve the toxicity and efficacy profiles of these agents. A tumor targeting system consists of a tumor recognition moiety linked to a cytotoxic payload. Antibody-drug conjugate...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-20
Budget: 04/15/07 - 11/14/07

DESCRIPTION (provided by applicant): Protein drugs have been approved for many therapeutic indications and represent a rapidly growing segment of the pharmaceutical industry. However, many approved protein drugs and candidates in development fail to reach their potential efficacy due to suboptimal pharmacokinetic properties and immunogenicity co...